Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
주식 순위 #33956
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
주가
$17.15
마지막 동기화: 2026-08-03
시가총액
$6.51M
변동 (1일)
9.80%
변동 (1년)
289.77%
국가
US
거래 Galera Therapeutics, Inc. (GRTX)

카테고리

Galera Therapeutics, Inc. (GRTX)의 주가 이력
최고 종가: $17.15 (2026-08-01 기준)

최저 종가: $2.54K (2019-11-01 기준)
Galera Therapeutics, Inc.의 주가 이력 (2019 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 98.59%
2025 -26.18%
2024 -76.56%
2023 -91.44%
2022 -45.34%
2021 -73.46%
2020 -7.59%
2019 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$517.18 32.51%
US
$857.76 31.47%
NL
$733.26 7.36%
CH
$1.07K -6.40%
KR
$257.99 13.97%
BE